496921-42-7

Basic information

• Product Name: Benzenesulfonamide, N-[2-[(methylsulfonyl)oxy]ethyl]-2-nitro-
• CAS NO: 496921-42-7
• Molecular Formula: C9H12N2O7S2
• Molecular Weight: 324.335
• Mol File: 496921-42-7.mol

Chemical Properties

• CAS DataBase Reference: Benzenesulfonamide, N-[2-[(methylsulfonyl)oxy]ethyl]-2-nitro-(CAS DataBase Reference)
• NIST Chemistry Reference: Benzenesulfonamide, N-[2-[(methylsulfonyl)oxy]ethyl]-2-nitro-(496921-42-7)
• EPA Substance Registry System: Benzenesulfonamide, N-[2-[(methylsulfonyl)oxy]ethyl]-2-nitro-(496921-42-7)

Safety Data

• Hazardous Substances Data: 496921-42-7(Hazardous Substances Data)

Upstream product

• 1694-92-4 2-Nitrobenzenesulfonyl chloride 
• 18226-11-4 N-(2-hydroxy-ethyl)-2-nitro-benzenesulfonamide 
• 124-63-0 methanesulfonyl chloride 

Downstream Products

• 1370451-42-5 1-[2-(2-aminophenylsulfonylamino)ethyl]-4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododecane 
• 1370451-36-7 1-[2-(2-nitrophenylsulfonylamino)ethyl]-4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododecane 
• 344951-14-0 (7-{(diethoxy-phosphoryl)-[2-(2-nitro-benzenesulfonylamino)-ethyl]-amino}-heptyl)-carbamic acid tert-butyl ester 
• 344951-18-4 [7-(2-bromo-acetylamino)-heptyl]-[2-(2-nitro-benzenesulfonylamino)-ethyl]-phosphoramidic acid diethyl ester 
• 344951-20-8 [4-(2-Nitro-benzenesulfonyl)-6-oxo-1,4,7-triaza-cyclotetradec-1-yl]-phosphonic acid diethyl ester 
• 344951-16-2 (7-amino-heptyl)-[2-(2-nitro-benzenesulfonylamino)-ethyl]-phosphoramidic acid diethyl ester 
• 344951-12-8 {7-[2-(2-nitro-benzenesulfonylamino)-ethylamino]-heptyl}-carbamic acid tert-butyl ester 
• 344951-10-6 N-[2-(7-amino-heptylamino)-ethyl]-2-nitro-benzenesulfonamide 
• 848356-52-5 5-(2-nitro-benzenesulfonyl)-3,3a,4,5,6,7-hexahydro-[1,2,3]triazolo[1,5-a]pyrazine 
• 848356-43-4 N-allyl-N-(2-azido-ethyl)-2-nitro-benzenesulfonamide 
• 848356-36-5 N-(2-azido-ethyl)-2-nitro-benzenesulfonamide 
• 344951-08-2 1-[(2-Nitrophenyl)sulfonyl]aziridine 

Relevant articles and documents

Carbazole compounds and therapeutic uses of the compounds

Compounds of the general structural formula (I) and (II) and use of the compounds and salts and hydrates thereof, as therapeutic agents are disclosed. Treatable diseases and conditions include cancers, inflammatory diseases and conditions, and immunodeficiency diseases. (I), (II).

Development of hypoxia-sensitive Gd3+-based MRI contrast agents

Hypoxia occurs in various diseases, including cancer, ischemia, and acute and chronic vascular diseases. Here we describe the design and synthesis of the first hypoxia-sensitive MRI contrast agents, SAGds. SAGds showed a pH-dependent r1 relaxivity change associated with intramolecular chelation of the nitrogen atom of the sulfonamide moiety to the Gd3+ center. There was a correlation between the pKa of the r1 relaxivity change and the sum of the Hammett σ constants of substituents on the aromatic ring. Among the synthesized compounds, 4NO22MeOSAGd was selectively reduced to the amine by rat liver microsomes under hypoxic conditions, resulting in a 1.8-fold increment of the r1 relaxivity owing to the change in pKa of the arylsulfonamide moiety. This enhancement of the r 1 relaxivity could be clearly detected in T1-weighted MR images. Thus, 4NO22MeOSAGd is a 'smart' MRI contrast agent for the detection of hypoxia under physiological conditions.

Intramolecular [2+3]-addition of an azide to a C=C double bond as a novel approach to piperazines

An intramolecular [2+3]-cycloaddition of an azide to a CC double bond was carried out to obtain hexahydro[1,2,3]triazolo[1,5-a]pyrazines. These compounds were used as intermediates to prepare 2-(halogenomethyl)piperazines that could serve as precursors fo

Facile synthesis of a selectively protected triazamacrocycle

1,7-Diaminoheptane was selectively homologated with the novel reagent N-(2-nitrobenzenesulfonyl)aziridine. A series of reactions then followed to afford a selectively protected 14-membered triazamacrocyclic ring.